专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

11. 发明申请

US20030175863A1 Influenza immunogen and vaccine 审中-公开
标题翻译：流感免疫原和疫苗
公开(公告)号：US20030175863A1
公开(公告)日：2003-09-18
申请号：US10080299
申请日：2002-02-21
发明人： Ashley J. Birkett
IPC分类号： C12P021/06 , C12P019/34 , A61K039/12 , A61K039/29
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/5258 , A61K2039/54 , A61K2039/555 , A61K2039/55555 , A61K2039/57 , C07K14/445 , C07K14/4711 , C07K14/50 , C07K2319/00 , C12N9/0077 , C12N2730/10122 , C12N2740/13022 , C12N2740/16222 , C12N2760/16122 , C12N2770/32122 , Y02A50/484
摘要： A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid protein (HBc) is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza epitope is preferably expressed at or near the N-terminus or in the HBc immunogenic loop sequence. The chimer preferably contains an influenza-specific T cell epitope and is preferably engineered for both enhanced stability of self-assembled particles and enhanced yield of those chimeric particles. Methods of making and using the chimers are also disclosed.
摘要翻译：公开了嵌合的羧基末端截短的乙型肝炎病毒核衣壳蛋白（HBc），其包含用于诱导产生针对流感M2蛋白的抗体的免疫原。免疫原性流感病毒表位优选在N末端或HBc免疫原性环序列中或附近表达。嵌合体优选含有流感特异性T细胞表位，并且优选地被设计用于增强自组装颗粒的稳定性和提高那些嵌合颗粒的产量。还公开了制造和使用这种开发者的方法。

12. 发明申请

US20030170258A1 Novel processes implementing selective immune down regulation (SIDR) 审中-公开
标题翻译：实施选择性免疫调节（SIDR）的新方法
公开(公告)号：US20030170258A1
公开(公告)日：2003-09-11
申请号：US10385440
申请日：2003-03-12
申请人： Enzo Therapeutics, Inc.
发明人： Jayanta Roy-Chowdhury , Yaron Ilan , Elazar Rabbani , Dean L. Engelhardt
IPC分类号： A61K039/12 , A61K039/29 , A61K039/02 , A61K039/21 , A61K038/13 , A61K031/739
CPC分类号： A61K45/06 , A61K31/739 , A61K39/001 , A61K48/00 , A61K2039/541 , A61K2300/00
摘要： Novel immune modulating processes are provided in which the imunological state of a subject including mature subjects, mammals and humans, are down regulated in a selective manner, and as a subset in a dominant manner. The novel immunological state termed SIDR for selective immune down regulation is usefully applied to the immunological modulation or regulation of gene delivery components, artificially expressed genes, gene delivery systems and expression products of artificially introduced genes by such delivery systems, and infectious agents. SIDR is also useful when combined with other immune modulating treatments such as general immune suppression and anti-apoptosis. SIDR may also be used to selectively down regulate the immune response system of a subject to a wide variety of noncellular immunogenic components and to native antigens. Other processes for producing immune suppression by administering macromolecules or compounds to a subject so as to obtain or effect SIDR are also provided. Kits for carrying out the novel processes are also provided.
摘要翻译：提供了新的免疫调节过程，其中包括成熟受试者，哺乳动物和人的受试者的免疫状态以选择性方式下调，并以主要方式作为子集。用于选择性免疫调节的称为SIDR的新型免疫学状态有效地应用于免疫调节或调节基因递送成分，人工表达的基因，基因递送系统和由这种递送系统人工引入的基因的表达产物和感染因子。当与其他免疫调节治疗如一般免疫抑制和抗细胞凋亡相结合时，SIDR也是有用的。 SIDR也可用于选择性地将受试者的免疫应答系统下调到多种非细胞免疫原性组分和天然抗原。还提供了通过向受试者施用大分子或化合物以获得或影响SIDR来产生免疫抑制的其它方法。还提供了用于执行新颖过程的套件。

13. 发明申请

US20030157132A1 Remedies for hepatitis c 失效
标题翻译：丙型肝炎的补救措施
公开(公告)号：US20030157132A1
公开(公告)日：2003-08-21
申请号：US10203754
申请日：2002-11-26
发明人： Seima Itami , Tatsurou Shibui , Makoto Seki , Yoshihisa Yotsumoto , Yoshiharu Matsuura , Tatsuo Miyamura
IPC分类号： C12P019/34 , A61K039/12 , A61K039/29 , C07K002/00 , C07K004/00 , C07K005/00 , C07K007/00 , C07K014/00 , C07K016/00 , C07K017/00 , A61K038/00 , C12N005/00 , C12N005/02
CPC分类号： A61K31/737 , A61K2039/505 , C07K16/109 , C07K2317/21 , C07K2317/622
摘要： The present invention provides a substance which inhibits the binding between E2/NS1 protein of hepatitis C virus and a cell infectious with hepatitis C virus, a cell expressing CD81, or CD81. The present invention can provide a novel medicament which has an anti-viral effects such as an inhibitory action against HCV infection.
摘要翻译：本发明提供抑制丙型肝炎病毒的E2 / NS1蛋白与感染丙型肝炎病毒的细胞，表达CD81或CD81的细胞的结合的物质。本发明可以提供具有抗HCV感染的抑制作用的抗病毒作用的新型药物。

14. 发明申请

US20030138458A1 HCV E1E2 vaccine compositions 审中-公开
公开(公告)号：US20030138458A1
公开(公告)日：2003-07-24
申请号：US10187257
申请日：2002-06-28
发明人： Michael Houghton , Stephen R. Coates , Derek O'Hagan
IPC分类号： C12Q001/68 , A61K031/70 , A01N043/04 , A61K039/12 , A61K039/29 , A61K045/00 , A61K047/00
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K2039/5555 , A61K2039/55561 , A61K2039/55566 , A61K2039/57 , C12N2770/24222 , C12N2770/24234
摘要： HCV E1E2 compositions comprising E1E2 antigens, submicron oil-in-water emulsions and/or immunostimulatory nucleic acid sequences are described. The compositions can be used in methods of stimulating an immune response in a vertebrate subject.

15. 发明申请

US20030124718A1 Vaccine composition 审中-公开
标题翻译：疫苗组成
公开(公告)号：US20030124718A1
公开(公告)日：2003-07-03
申请号：US10147910
申请日：2002-05-20
发明人： Deborah Fuller , James Fuller , Joel Haynes , Timothy Shipley
IPC分类号： C12Q001/68 , C07H021/04 , C12N009/64 , C12P021/02 , C12P021/06 , A61K039/12 , C12N015/00 , C12N015/09 , C12N015/63 , C12N015/70 , C12N015/74 , C12N005/08 , A61K039/29
CPC分类号： C07K14/005 , A61K39/00 , A61K48/00 , A61K2039/5256 , A61K2039/53 , A61K2039/57 , C12N15/895 , C12N2730/10122 , C12N2740/15022 , C12N2740/16022 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322 , C12N2750/14143
摘要： Recombinant nucleic acid molecules are described. The molecules have a first nucleic acid sequence encoding in antigen containing two or more cytolytic T lymphocyte (CTL) epitopes, wherein said epitopes are selected from the amino acid sequences of SEQ ID NOs: 1, 2, 3, 4, 5 and 6 and analogues of any thereof which can be recognised by a CDS8null T cell that recognises an epitope with the amino acid sequence of any one of SEQ ID NOs: 1, 2, 3, 4, 5 or 6. Peptides encoded by the molecules and vectors and compositions containing these molecules are also described. Methods of eliciting an immune response using these molecules are also described.
摘要翻译：描述重组核酸分子。所述分子具有编码在含有两个或多个细胞溶解性T淋巴细胞（CTL）表位的抗原中的第一核酸序列，其中所述表位选自SEQ ID NO：1,2,3,4,5和6的氨基酸序列，其任何一个的类似物可以被识别具有SEQ ID NO：1,2,3,4,5或6中任一个的氨基酸序列的表位的CDS8-T细胞识别。由分子和载体编码的肽并且还描述了含有这些分子的组合物。还描述了使用这些分子引发免疫应答的方法。

16. 发明申请

US20030108861A1 Method of large scale production of Hepatitis A Virus 失效
标题翻译：大规模生产甲型肝炎病毒的方法
公开(公告)号：US20030108861A1
公开(公告)日：2003-06-12
申请号：US10006882
申请日：2001-12-10
发明人： Heidi Meyer , Manfred Reiter , Wolfgang Mundt , Noel Barrett , Friedrich Dorner
IPC分类号： C12N007/00 , C12Q001/70 , A61K039/29 , C12N007/01 , C12N007/02
CPC分类号： C12N7/00 , A61K39/12 , A61K39/29 , A61K2039/5252 , C12N2770/32434 , C12N2770/32451 , Y02A50/464
摘要： The present invention provides methods of large scale production of Hepatitis A Virus (HAV) on VERO cells bound to microcarrier. The invention also provides for methods of isolation of HAV from the cell culture supernatant of HAV infected VERO cells.
摘要翻译：本发明提供了在与微载体结合的VERO细胞上大规模生产甲型肝炎病毒（HAV）的方法。本发明还提供从HAV感染的VERO细胞的细胞培养物上清液中分离HAV的方法。

17. 发明申请

US20030013118A1 METHODS OF DETERMINING RESISTANCE TO TREATMENT FOR HEPATITIS C VIRUS 审中-公开
标题翻译：确定抗病毒治疗C型病毒的方法
公开(公告)号：US20030013118A1
公开(公告)日：2003-01-16
申请号：US09406997
申请日：1999-09-28
发明人： ALBERT EDGE , NEZAM H. AFDHAL
IPC分类号： C12Q001/70 , G01N033/53 , C12P021/06 , A61K039/29
CPC分类号： G01N33/5767 , G01N33/6869 , G01N2333/18 , G01N2333/54 , G01N2333/56 , G01N2800/52
摘要： Methods for identifying hepatitis C virus (HCV)-infected subjects responsive to treatment for HCV infection or unlikely to respond to treatment for HCV infection are described. The level of Th2 cytokines in the subject during treatment serves as an indicator of whether the subject is likely to respond to treatment for HCV, e.g., interferon treatment. An elevated level of at least one Th2 cytokine during treatment indicates that an HCV-infected subject is unlikely to respond to a treatment for HCV. A decreased level of at least one Th2 cytokine indicates that an HCV-infected subject is responsive to a treatment for HCV. In a preferred embodiment, IL-10 levels are detected to identify subjects responsive to or unlikely to respond to interferon treatment.
摘要翻译：描述了鉴定丙型肝炎病毒（HCV）感染的受试者对HCV感染的治疗或对HCV感染的治疗不能应答的方法。治疗期间受试者中Th2细胞因子的水平用作对象是否可能对HCV治疗有反应的指标，例如干扰素治疗。在治疗期间升高的至少一种Th2细胞因子水平表明HCV感染的受试者不太可能对HCV的治疗作出反应。至少一种Th2细胞因子的降低水平表明HCV感染的受试者对HCV的治疗有反应。在优选实施方案中，检测IL-10水平以鉴定对干扰素治疗有反应或不可能响应的受试者。

18. 发明申请

US20020192235A1 NOVEL VITAMIN B12 - BIODEGRADABLE MICRO PARTICULATE CONJUGATE CARRIER SYSTEMS FOR PERORAL DELIVERY OF DRUGS, THERAPEUTIC PEPTIDES/PROTEINS AND VACCINES 失效
标题翻译：新维生素B12 - 生物可降解的微粒子结合载体系统用于药物，治疗肽/蛋白质和疫苗的递送
公开(公告)号：US20020192235A1
公开(公告)日：2002-12-19
申请号：US09795979
申请日：2001-03-01
发明人： Kishore Babu Chalasani , Vamanrao Diwan , Kondapuram Vijaya Raghavan , Gregory John Russell-Jones , Sanjay Kumar Jain , Kollipara Koteshawar Rao
IPC分类号： A61K039/106 , A61K039/29 , A61K038/28 , A61K038/21 , A61K038/17 , A61K031/714 , A61K031/727 , A01N043/04
CPC分类号： A61K9/5153 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/167 , A61K9/5026 , A61K9/5031 , A61K9/5036 , A61K47/54 , Y02A50/472 , Y02A50/484 , Y10S977/906
摘要： The invention relates to a novel complex for oral delivery of drugs, therapeutic protein/peptides and vaccines which are loaded in a Vitamin B2 (VB12) coupled particulate carrier system with spacers in between, the carrier system with spacers having a formula VB12-Rnull/Rnull-N wherein, Rnull or Rnull is spacer and/or agents for derivatization of VB12 to provide either NH2 or COOH or SH groups, and N is the micro or nano particle carriers for the delivery of injectable drugs, therapeutic protein/peptides and vaccines.
摘要翻译：本发明涉及用于口服递送药物的新型复合物，治疗性蛋白质/肽和疫苗，其加载在维生素B2（VB12）偶联的颗粒载体系统中，其间具有间隔物，载体系统与具有式VB12-R' / R“ - N，其中R'或R”是间隔基，和/或用于VB12衍生化以提供NH 2或COOH或SH基团的试剂，N是用于递送可注射药物的微粒或纳米颗粒载体，治疗性蛋白质/肽和疫苗。

19. 发明申请

US20020182222A1 HIV vaccine candidate peptides 审中-公开
标题翻译： HIV疫苗候选肽
公开(公告)号：US20020182222A1
公开(公告)日：2002-12-05
申请号：US10055524
申请日：2001-10-26
发明人： Anne De Groot
IPC分类号： A61K048/00 , A61K039/21 , A61K039/29 , C12N009/22
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/53 , A61K2039/57 , C07K2319/00 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322
摘要： The invention provides HIV vaccine candidates that have nullevolvednull due to gene shuffling in vitro for inclusion of nullcross-cladenull characteristics. The invention also provides a method for identifying HIV vaccine candidates that could be presented in the context of more than one HLA, due to the creation of promiscuous epitopes by gene shuffling.
摘要翻译：本发明提供了由于体外基因改组而包含“交叉进化”特征而“演化”的HIV疫苗候选物。本发明还提供了一种用于鉴定可以在多于一种HLA的上下文中呈递的HIV疫苗候选物的方法，因为通过基因改组产生混杂表位。

20. 发明申请

US20020064533A1 HBV core antigen particles with multiple immunogenic components attached via peptide ligands 有权
标题翻译：具有通过肽配体连接的多种免疫原性组分的HBV核心抗原颗粒
公开(公告)号：US20020064533A1
公开(公告)日：2002-05-30
申请号：US09873459
申请日：2001-06-04
发明人： Kenneth Murray
IPC分类号： C07K005/00 , A61K038/04 , A61K039/112 , C07K007/00 , A61K039/165 , A61K039/275 , A61K039/29 , A61K039/08 , A61K039/002 , C07K017/00 , A61K039/12 , A61K039/04 , C07K016/00
CPC分类号： A61K39/385 , A61K39/00 , A61K39/12 , A61K39/29 , A61K39/292 , A61K2039/5258 , A61K2039/6075 , A61K2039/627 , A61K2039/64 , C07K14/005 , C07K2319/00 , C07K2319/70 , C12N7/00 , C12N2730/10122 , C12N2730/10123 , C12N2730/10134 , G01N33/56983 , G01N2333/02 , G01N2469/20 , Y02A50/386 , Y02A50/388 , Y02A50/396 , Y02A50/412 , Y02A50/464 , Y02A50/466 , Y02A50/472 , Y02A50/484 , Y02A50/52 , Y02A50/53 , Y02A50/54 , Y02A50/58 , Y02A50/59 , Y02A50/60 , Y10S530/806 , Y10S530/81
摘要： This invention relates to hepatitis B virus (nullHBVnull) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.
摘要翻译：本发明涉及以多种免疫原特异性为特征的乙型肝炎病毒（“HBV”）核心抗原颗粒。更具体地，本发明涉及包含免疫原，表位或其它相关结构的HBV核心抗原颗粒，其通过配体选择性地结合HBV核心蛋白的配体进行交联。这样的颗粒可以用作各种免疫原性表位的递送系统，包括HBV衣壳结合肽，其有利地还通过阻断HBV核心蛋白和HBV表面蛋白之间的相互作用来抑制和干扰HBV病毒装配。不同免疫原和/或衣壳结合肽配体的混合物可以交联到相同的HBV核心颗粒。这样得到的多组分或多价HBV核心颗粒可以有利地用于治疗和预防性疫苗和组合物，以及使用它们的诊断组合物和方法中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式